Our ground-breaking pharmaceutical technology is revolved around targeting and treating mitochondria. One approach we are pursuing is targeting very late-stage or metastatized cancer (stage IV). For this, we are initially going to focus on treating pancreatic cancer, which currently does not have very effective chemotherapeutic options. We are close to starting our initial trial runs at the University of California, San Diego (UCSD) with some of our lead candidate small molecule chemotherapeutic drugs. Our small molecule technology also has the ability to help maintain more normal-like homeostatic conditions in mitochondria, while helping to prevent apoptosis, which will have major implications in various pathologies such as Alzheimer's, organ failure, hearing loss, amongst many others. We are currently pursuing these avenues as well.